We read with interest the paper from Navarro-Millan about the use of anakinra in severe COVID-19 patients (1). On the other hand, there is the issue of patients treated with anakinra for their underlying condition and who develop COVID-19 (2).
The COVID-19 outbreak dramatically changed hospital everyday life, impairing the course of previous routine activity, also in urology. In the next months, together with keeping the focus on the prevention of contagion recrudescence, the health care…